Two independent radioimmunoassay techniques for the major phenobarbital-inducible cytochrome P-450 (PB P-450) of rat liver microsomal membranes are described. The first technique employs as the source of radiolabelled antigen the products of translation in vitro labelled with [35Slmethionine. The second technique employs purified antigen labelled with 1251 and is quicker, less expensive and more precise. Both assays are highly specific for PB P-450 and can detect quantities of this variant as small as 1 ng. This is several orders of magnitude more sensitive than any method described previously for the quantification of cytochromes P-450, and consequently the technique is particularly well suited for the quantification of so-called constitutive cytochrome P-450 variants that are present in very low amounts. The results of the radioimmunoassays demonstrate that the apparent 2.6-fold induction of total cytochromes P-450 after phenobarbital treatment is due to a 43-fold increase in PB P-450. Although f,-naphthofiavone increases the total content of cytochrome P-450 of microsomal membranes 1.4-fold, it actually causes a 55% decrease in the amount of PB P-450. Thus different xenobiotics can have differential effects on the expression of the genes for specific cytochrome P-450 variants.
barbital and,B-naphthoflavone. Different variants of cytochrome P-450 can be induced by different xenobiotics, and thus an absolute requirement for studying the molecular biology of the induction process is an assay that is sensitive, accurate and specific for a single cytochrome P-450 variant. Enzyme assays using specific substrates have limited use because of overlap in the substrate specificities of individual variants (Johnson, 1979) . Fortunately there is a much higher degree of individual specificity in the immunochemical characteristics of the different cytochrome P-450 variants, and our approach has been to develop radioimmunoassays specific for individual cytochromes P-450.
We previously developed a radioimmunoassay for the major cytochrome P-450 variant induced by phenobarbital in rat liver microsomal membranes (PB P-450). This assay was based on the use of 35S-labelled products of translation of polyribosomes in vitro as the source of radiolabelled antigen (Phillips et al., 1981) . The results obtained showed that the small increase observed in the specific content of total cytochromes P-450 after treatment with phenobarbital was due to a large induction of a specific cytochrome P-450 variant. The studies reported in the present paper demonstrate the specificity of the radioimmunoassay and extend the results to include the effect of fl-naphthoflavone (a class II inducer) on PB P-450. We also report the development of a quicker, less expensive and more accurate radioimmunoassay technique for PB P-450 based on the use as the radiolabelled antigen of purified PB P-450 labelled in vitro with 1251. The results from both radioimmunoassays demonstrate that the amount of PB P-450 in rat liver microsomal membranes is greatly increased by phenobarbital, but is decreased by fi-naphthoflavone.
Materials and methods

Animals
Male Sprague-Dawley rats (180-200g) bred at the University College animal facility were used in these experiments. The rats were fed (diet GR3 EK; Dixons and Sons, Ware, Herts., U.K.) and watered ad libitum under controlled lighting conditions of 12h light/12h dark. Rats treated with sodium phenobarbital were fed with a 0.1% (w/v) solution for 4 days and injected intraperitoneally on day 5 with a 4% (w/v) solution of sodium phenobarbital in 0.9% (w/v) NaCl (saline) at a dose of 40mg/kg. Rats treated with 16-naphthoflavone were injected daily for 3 days with a 0.3 ml injection of finaphthoflavone in corn oil at a dose of 40mg/kg.
Control animals received injections of 0.9% NaCl or corn oil. No difference in the amount of total cytochromes P-450 or of PB P-450 was observed when animals were treated with saline or corn oil. Animals were starved overnight before use and killed by cervical dislocation. Isolation and solubilization of microsomal membrane vesicles
The following procedures were performed at 40C. Total microsomal membrane vesicles were isolated from liver as described by van der Hoeven & Coon (1974) . The microsomal membrane pellet was resuspended (at a final protein concentration of about 20ng/ml) in 10mM-potassium phosphate buffer (pH 7.25) containing 2096 (v/v) glycerol/ 1 mM-EDTA, then flushed with nitrogen and stored at -78oC.
Microsomal membrane vesicles were thawed, flushed with nitrogen, homogenized briefly and solubilized by a modification of the procedure of Imai (1976) . Membrane vesicles were diluted to a final protein concentration of 1.9mg/ml in 100mM-potassium phosphate buffer (pH 7.25)/20Yo glycerol/i mM-dithiothreitol/I mM-EDTA/24uM-FMN/ 23 #uM-butylated hydroxytoluene/0.4 mM-phenylmethanesulphonyl fluoride. A 20% (w/v) solution of recrystallized sodium cholate (Guengerich, 1978) was added dropwise, with stirring at 0°C to a final concentration of 0.7% (w/v) (Guengerich & Martin, 1980 agitated and left for 1 h at room temperature with occasional shaking. The reaction was terminated by adding 0.5 ml of 0.2M-glycine in buffer A and incubating for a further 2min. 125I-labelled protein was separated from unincorporated Bolton & Hunter reagent by Sephadex G-75 column chromatography. The column (0.9cm x 30 cm) had been previously equilibrated with buffer A at room temperature, washed with 100mg of bovine serum albumin (Sigma, fraction V, RIA grade) and re-equilibrated with buffer A. The iodinated protein was eluted with buffer A containing 0.25% (w/v) gelatin; 1 ml fractions were collected into tubes containing 100,ul of bovine serum albumin at a concentration of 60mg/ml. The fractions containing iodinated PB P-450 were made 1% with respect to both Triton X-100 and sodium deoxycholate and stored in batches at -780C.
Radioimmunoassay of PB P-450 with '251-labelled All radioimmunoassays were performed in a final (Lincoln's Inn Fields, London) and were prepared for use as described previously (Phillips et al., 1981) , except that sodium deoxycholate was present in the first wash buffer at a final concentration of 1% and methionine was omitted from both wash buffers.
Radioimmunoassay of PB P-450 with 35S-labelled PB P-450 [35SlMethionine-labelled products of translation in vitro were used as a source for labelled PB P-450 in a radioimmunoassay as described previously (Phillips et al., 1981) .
SDS/polyacrylamide-gel electrophoresis
Purified proteins and microsomal membrane samples were analysed on 100/o-acrylamide slab gels containing SDS as described previously (Phillips etal., 1981) .
Ouchterlony double-immunodiffusion analysis This was done as described by Thomas et al. (1981) . Antiserum was concentrated to 200mg/ml in an Amicon Minicon B clinical sample concentrator.
Determination oftotal cytochromes P-450
Cytochrome P-450 was assayed by the COreduced difference-spectral method of Omura & Sato (1964) . Protein concentrations were determined by the method of Lowry et al. (1951) , with bovine serum albumin as the standard. Samples containing non-ionic detergents were assayed for protein content by the method of Wang & Smith (1975) .
Results
Purification ofPB P-450 and NF P-450
The major cytochrome P-450 variants induced by phenobarbital (PB P-450) and ,-naphthoflavone (NF P-450) were purified by chromatography on n-octylamino-Sepharose 4B and DEAE-cellulose columns to specific activities of 18.4 and 17.4nmol/ mg of protein respectively (E. A. Shephard, I. R. Phillips, U. Gaul, S. F.. Pike & R. M. Bayney, unpublished work). Analysis by electrophoresis on SDS/polyacrylamide gels (Fig. 1 ) demonstrated that both these protein preparations were homogeneous and that each cytochrome P-450 variant was apparently free of contamination by the other. On these gels the molecular weight of PB P-450 is 52000 and that of NF P-450 is 54000.
Specificity ofantibodies to PB P-450
The apparent homogeneity of the PB P-450 does not rule out the possibility of contamination by small amounts of other microsomal proteins, which could also produce antibodies on injection into rabbits. This risk was lessened by the use of a protocol specifically designed to favour strongly the selective production of antibodies against only the major antigen. This procedure has been demonstrated to give this selectivity even in the presence of amounts of contaminating proteins that are visible on SDS/ polyacrylamide gels (Harboe & Inglid, 1973; E. A. Shephard, unpublished work) . Antiserum raised by this method to purified PB P-450 gave a single immunoprecipitation band on reaction with purified Vol. 212 using an antibody raised to PB P-450 Antiserum (200mg/ml) was placed in the centre well. Solubilized microsomal membranes isolated from control (4.5mg/ml), ,-naphthoflavone-treated (4.5mg/ml) or phenobarbital-treated (3.8mg/ml) rats were placed in wells a, b and c respectively. Purified PB P-450 (0.2mg/ml), purified NF P-450 (0.2mg/ml) and purified NADPH-cytochrome P-450 reductase (0.2mg/ml) were placed in wells d, e and f respectively. All samples were added in a volume of 12,u1. Plates were incubated in a moist chamber at room temperature. Precipitin bands formed between the antiserum and either PB P-450 or membranes isolated from phenobarbital-treated animals were visible within 2h, and those formed between the antiserum and the other solubilized microsomal membranes were visible after 24 h. PB P-450 by Ouchterlony double immunodiffusion (Fig. 2) . No cross-reactivity was observed between the anti-(PB P-450) serum and purified NF P-450 or NADPH-cytochrome P-450 reductase. A single immunoprecipitation band was also formed between the antiserum and solubilized total liver microsomal membrane proteins isolated from phenobarbital-or fJ-naphthoflavone-treated or control rats (Fig. 2) . The band formed between the antiserum and purified PB P-450 gave a fusion pattern of identity with that formed between the antiserum and the microsomal membrane proteins. The band formed between the antiserum and microsomal membrane proteins isolated from phenobarbital-treated rats is more intense than that formed between the antiserum and microsomal membrane proteins from either ,6-naphthoflavone-treated or control animals (Fig. 2) . These data suggest that the antiserum is specific for a single microsomal membrane protein (namely PB P-450) that is present in greater amounts in microsomal fractions of phenobarbital-treated rats. Further evidence for the specificity of anti-(PB P-450) antibodies is provided by our previous finding that the antibodies precipitate a single polypeptide band ofthe same molecular weight as purified PB P-450 from the products of liver RNA translation in vitro (Phillips et al., 1981) , but not from the translation products of soleus-muscle poly(A)-containing RNA (Shiels et al., 1982) or pancreas total RNA (I. R. Phillips, E. A. Shephard & M. White, unpublished work).
15S radioimmunoassay ofPB P-450
A far more sensitive test for cross-reactivity of anti-(PB P-450) antibodies with other microsomal membrane proteins is provided by radioimmunoassay. Competition curves of purified PB P-450 and NF P-450 (Fig. 3) were obtained by using 35S-labelled products of translation in vitro as a source of labelled PB P-450 in the radioimmunoassay system described previously (Phillips et al., 1981 quantify a specific cytochrome P-450 variant in microsomal membranes, this particular radioimmunoassay technique is too expensive and timeconsuming for the routine assay of relatively large numbers of samples. Therefore we developed a less complicated, more rapid and less expensive radioimmunoassay technique based on purified PB P-450 labelled in vitro with 1251 as the radiolabelled antigen.
Radioiodination ofPB P-450
When purified PB P-450 was radioiodinated with the Bolton & Hunter reagent as described in the Materials and methods section, 18% of the radioactivity was incorporated into the protein, giving a specific radioactivity of 18,uCi/pg. Specificity of the interaction between 1251-labelled PB P-450 and anti-(PB P-450) serum A maximum of about 60%o of the '251-labelled PB P-450 was precipitable by anti-(PB P-450) serum (Fig. 4a) , indicating that the antiserum is still able to interact with PB P-450 after the latter had been radioiodinated. The inability of the antiserum to precipitate all the iodinated antigen is not unusual (see, e.g., Heath et al., 1982) and is probably due to either the blocking of some of the antigenic sites by the incorporated Bolton & Hunter reagent or radiation damage to the protein. The specificity of the immunoprecipitation reaction was demonstrated by determining the effect of substituting different antigens or antibodies. Anti-(PB P-450) serum was unable to precipitate 1251-labelled NADPH-cytochrome P-450 reductase (Fig. 4b) , and '251-labelled PB P-450 was precipitable only by anti-(PB P-450) serum and not by non-immune or anti-(NF P-450) serum (Fig. 4a) .
Specificity ofradioimmunoassayfor PB P-450
It was first necessary to establish that unlabelled purified PB P-450 could compete with the radioiodinated antigen for binding sites on the antibody under the conditions used for the immunoprecipitation reaction. Radioiodinated PB P-450 was mixed with various amounts of unlabelled PB P-450, and a quantity of antiserum, sufficient to precipitate 500/o of the total precipitable radioactivity in the absence of any competitor protein, was added. Samples were processed as described in the Materials and methods section. Fig. 5 shows that PB P-450 competes for essentially all the antibodybinding sites that recognize the radioiodinated antigen. The assay was capable of detecting PB P-450 in amounts as low as 1ng (-20fmol ) and could be used to measure quantities up to lOOng (2pmol). We routinely use up to lOO,ug of competitor protein in the assay. Thus it is possible to detect PB P-450 in amounts as low as lOng/mg of 0), with anti-(PB P-450) serum isolated from a different rabbit (0), with antiserum to PB P-450 purified by a different method (described in the text) (), or with the anti-(PB P-450) serum used in curve 0 after having been made 'variant-specific' (A). The amount of each antiserum used was sufficient to precipitate 500/o of the total immunoprecipitable radioactivity in the absence of competitor. Antibody-antigen complexes were precipitated with Staph. aureus cells.
After subtraction of the amount immunoprecipitated by non-immune serum (approx. 2.5% of total), radioactivity in the pellet was expressed as the percentage of that immunoprecipitated in the absence of competitor. the sensitivity of the assay is the upper conconcentration at which it is possible to solubilize microsomal membrane proteins. Thus it is possible with this assay to detect amounts of PB P-450 as low as 0.1 ng/mg of protein and concentrations as low as 2 pM. As a control for interference by microsomal membrane proteins other than cytochrome P-450, NADPH-cytochrome P-450 reductase was used as a competitor protein. This had no effect on the assay when added at lO,ug (i.e. <0.01% cross-reactivity) (Fig. 5) . A more exacting test of the specificity of the radioimmunoassay is the degree of cross-reactivity observed with other cytochrome P-450 variants. A very small (-1.5%) degree of cross-reactivity was observed between purified NF P-450 and anti-(PB P-450) serum (Fig. 5) . This was significantly more than was found for the [35S]-methionine-based radioimmunoassay (Fig. 3) . Since the purified NF P-450 and the anti-(PB P-450) serum were the same in both radioimmunoassay Vol. 212 systems, the differences in cross-reactivity must be due to some difference in the labelled PB P-450. Perhaps modification during radioiodination produces some labelled PB P-450 molecules with affinity for the antibody decreased sufficiently to permit NF P-450 to compete with them for antibody binding sites.
Before using the 251I-based radioimmunoassay to quantify PB P-450, we attempted to decrease the cross-reactivity. Anti-(PB P-450) sera of different titres, raised in different rabbits, and antisera raised to PB P-450 purified by an entirely different method [precipitation with (NH4)2SO4, followed by column chromatography on DEAE-cellulose, CM-cellulose and hydroxyapatitel, all gave essentially the same degree of cross-reactivity (Fig. 5) . It should be possible to remove, by affinity chromatography, antibodies that recognize antigenic sites common to both PB P-450 and NF P-450. By the technique of Thomas et al. (1979) , anti-(PB P-450) serum was passed through a column of partially purified NF P-450 (specific activity 12.6nmol/mg of protein) bound to CNBr-activated Sepharose 4B. Antibodies that did not bind to the column were collected in small fractions and tested for cross-reactivity with purified NF P-450. However, these antibodies still exhibited the same degree of cross-reactivity with NF P-450 (Fig. 5) . This was probably not due to a failure of the column to bind antibodies to NF P-450, because we have affinity-purified IgG species for NADPH-cytochrome P-450 reductase and serum albumin under similar conditions (E. A. Shephard & S. F. Pike, unpublished work). Fig. 5 shows that the radioimmunoassay for PB P-450 does not detect amounts of NF P-450 less than lOOng. Thus the cross-reactivity could cause potential difficulties only when assaying small amounts of PB P-450 in the presence of large amounts of NF P-450, for example when assaying membranes isolated fromf,-naphthoflavone-or 3-methylcholanthrene-treated animals. However, even for these maximally unfavourable situations the errors are negligible, since every lOng of NF P-450 in excess of l00ng is assayed as only 0.15 ng of PB P-450.
251I-based radioimmunoassay ofPB P-450 in microsomal membranes The technique was used to determine the amount of PB P-450 in solubilized liver microsomal membrane vesicles isolated from phenobarbital-or fl-naphthoflavone-treated or untreated rats (Fig. 6 ).
The amount of PB P-450 in control animals was 2.9,ug/mg of microsomal membrane protein, and 4.2% of the total cytochromes P-450 (Table 1) Protein competitor (pg) Fig. 6 . Radioimmunoassay by the 1251I method of PB P-450 in liver microsomal membrane vesicles isolated from phenobarbital-treated, fI-naphthoflavone-treated and control rats 1251-labelled PB P-450 (2 x 104c.p.m.) was mixed with the indicated amounts of unlabelled purified PB P-450 (-), or with solubilized microsomal membranes isolated from the livers of phenobarbitaltreated (0), 16-naphthoflavone-treated (J) or untreated (U) rats. Mixtures were incubated with an amount of anti-(PB P-450) serum sufficient to precipitate 50% of the total immunoprecipitable radioactivity. Antibody-antigen complexes were precipitated with Staph. aureus cells. After subtraction of the amount immunoprecipitated by non-immune serum, radioactivity in the pellets was expressed as the percentage of that immunoprecipitated in the absence of competitor.
tion of PB P-450. The very low amount of PB P-450 detected by this radioimmunoassay in control microsomal membranes demonstrated the lack of cross-reactivity between the many constitutive cytochrome P-450 variants and anti-(PB P-450) serum. A more exacting test of the assay is provided by the experiment using microsomal membranes from animals treated with f,-naphthoflavone. This caused a 1.4-fold induction of the total cytochromes P-450 content of rat liver microsomal membranes. However, the amount of PB P-450 was found to be decreased on treatment with this xenobiotic from 2.9 to 1.3,pg/mg of microsomal membrane proteins, representing a net decrease in amount of 55%. The relative proportion of this cytochrome P-450 variant as a percentage of the total cytochromes P-450 decreased from 4.2 to 1.3. The results obtained by the 125I radioimmunoassay ( Fig. 6 ; Table 1) were very similar to those obtained with the 35S radioimmunoassay ( Fig. 3 ; Table 1 ), demonstrating that any alteration or damage sustained by the PB P-450 during radioiodination in vitro did not affect the results obtained by radioimmunoassay.
Further evidence for the decrease in certain cytochromes P-450 after xenobiotic treatment is provided by the finding ( Table 1 ) that phenobarbital treatment, although greatly increasing PB P-450, causes an overall decrease in the amount of total non-phenobarbital-inducible cytochromes P-450.
Discussion
We have developed two independent radioimmunoassay techniques for the precise quantification of a specific cytochrome P-450 variant. The first involved the use of [35Slmethionine-labelled products of translation in vitro as a source of radiolabelled antigen, and the second used 1251-labelled purified PB P-450. The latter method is operationally simpler and very much cheaper, and is the method of choice. It involves no manual measurement, is several orders of magnitude more sensitive and is more precise than the other techniques used immunochemically to quantify specific cytochrome P-450 variants, such as radial immunodiffusion , rocket immunoelectrophoresis (Pickett et al., 1981) , or gel electrophoresis followed by immunochemical staining (Guengerich et al., 1982 ). An additional advantage of the radioimmunoassay over other techniques is that it is possible to check for very low extents of cross-reactivity. The specificity of our antibodies compared favourably with that reported by Thomas et al. (1979) and is greater than that found by Dus et al. (1980) or Guengerich et al. (1981) . The 1251 radioimmunoassay is particularly well suited to the quantification of small amounts of specific cytochrome P-450 variants present in 'control' samples, in addition to samples from animals treated with a variety of inducers. The technique should be extremely useful for the analysis of so-called 'constitutive' forms of cytochrome P-450.
We have shown, using both radioimmunoassay techniques, that phenobarbital causes an approximately 43-fold induction of PB P-450, whereas fJ-naphthoflavone depresses the amount of this cytochrome P-450 below the low values present in controls. Our results confirm and extend those of Thomas et al. (1979 Thomas et al. ( , 1981 by radial immunodiffusion, Pickett et al. (1981) by rocket immunoelectrophoresis and Guengerich et al. (1982) by electrophoresis followed by immunochemical staining. They support our earlier conclusion (Phillips et al., 1981) that the relatively small (2-3-fold) induction of the specific content of cytochromes P-450 in rat liver microsomal membranes by phenobarbital is due mainly to a large increase in the amount of a specific cytochrome P-450 variant (PB P-450). The larger phenobarbital induction of PB P-450 found in the present study compared with that reported previously (Phillips et al., 1981) is probably due to a difference in the regime of phenobarbital treatment, which results in a greater increase 1983 62 'IL in the specific content of total cytochromes P-450. ,-Naphthoflavone treatment, although inducing a different cytochrome P-450 variant (namely NF P-450) does not induce PB P-450, indicating that the induction of specific cytochrome P-450 variants occurs via a very selective mechanism.
The results in Table 1 and those found previously by Phillips et al. (1981) give indirect evidence that long-term phenobarbital treatment causes a decrease in the total amount of non-phenobarbitalinducible cytochromes P-450. This suggests that, in addition to causing an increase in one or a few specific cytochrome P-450 variants, a xenobiotic can decrease the amounts of other cytochrome P-450 variants. Several other groups have drawn attention to this possibility from results obtained by one-and two-dimensional gel electrophoresis (McIntosh et al., 1980; , and from the observed decrease in testosterone 16a-hydroxylase activity in microsomal membranes after treatment by 3-methylcholanthrene (Kuntzman et al., 1968; Kremers et al., 1978) .
The radioimmunoassay data reported in the present study provide direct evidence that ,B-naphthoflavone treatment decreases the quantity of PB P-450. Thus the process of induction of cytochromes P-450 by xenobiotics could be more complicated than originally thought, involving both a large increase of one or a few specific cytochrome P-450 variants from a low content in control membranes, together with a decrease in the amounts of other cytochrome P-450 variants. Analysis by a radioimmunoassay specific for NADPH-dependent cytochrome P-450 reductase of the same solubilized microsomal membrane preparations from control and ,B-naphthoflavone-treated animals showed that f,-naphthoflavone treatment had no effect on the amount of this enzyme (Shephard et al., 1983) . This indicates that the repressive effect of this xenobiotic on components of the mixed-function mono-oxygenase system is at least partially specific to PB P-450.
The decrease in PB P-450 on treatment by fJ-naphthoflavone could be due to an induced proliferation of microsomal membranes that has been reported Orrenius et al., 1965; Fouts & Rogers, 1965; Staubli et al., 1969; Phillips et al., 1981) , with no compensating increase in the expression of PB P-450 genes. However, we have found that fJ-naphthoflavone treatment results in a 53% decrease in translatable mRNA coding for PB P-450 , indicating that the observed decrease of the protein by this xenobiotic could be due to a decrease in PB P-450 gene expression.
During the course of this investigation, have reported the existence of as many as four phenobarbital-inducible cytochrome P-450 variants that have >95% fingerprint homology and Vol. 212 are immunochemically identical. It should be noted that these cytochrome P-450 variants were identified in Long-Evans and Holtzmann rat strains, and they vary between strain and breeding colony. In any one breeding colony only two or three of the phenobarbital-induced variants were present. Although it is not clear whether a similar microheterogeneity exists in the phenobarbital-inducible cytochrome P-450 of mature Sprague-Dawley rats of the University College breeding colony, this possibility must be considered. The existence of multiple, immunochemically indistinguishable, phenobarbital-inducible cytochrome P-450 variants would mean that the immunochemical quantification of a 'specific' cytochrome P-450 variant would, in fact, represent the sum of all the immunochemically indistinguishable cytochrome P-450 variants. Owing to the similarity of the molecular weights of these proteins, even the technique of electrophoresis in one dimension followed by immunochemical staining (Guengerich et al., 1982) could not distinguish them adequately. If we assume that our radioimmunoassay detects multiple related cytochrome P-450 variants, this will not affect our main conclusions that the induction process involves the enhanced expression of genes for specific cytochrome P-450 variants.
The observed 43-fold induction by phenobarbital of PB P-450 would then represent the average induction of all the proteins immunoprecipitated, with the possibility that there is even greater enhancement of the expression of particular genes. Thus the small increase in total cytochrome P-450 content after phenobarbital treatment is due to a relatively very much larger induction of one or a few specific cytochrome P-450 variants, which represent only a small proportion of the cytochromes P-450 in microsomal membranes from control rats. f,-Naphthoflavone treatment decreases the amount of at least one cytochrome P-450 variant that is induced by phenobarbital.
